The 2025 flu season in China, dominated by the AH3N2 strain, has led to a surge in pediatric cases and overwhelmed fever clinics. In response, digital health platforms are offering alternatives like at-home testing via courier services and telemedicine linked to public hospitals, enabling diagnosis and treatment from home. While convenient, these methods come with caveats: false negatives from improper test use, lack of standardization, and limited diagnostic depth compared to in-person care. High-risk groups are still advised to seek immediate medical attention. Preventive tools like 'liquid masks'—nasal sprays claiming viral protection—lack scientific backing and regulatory approval. Meanwhile, official surveillance data remains crucial for tracking vaccine efficacy and outbreak trends. The episode also touches on personal experiences, including attending a vibrant badminton championship in Hangzhou and reflections on holiday traditions in China.